新辅助化疗治疗乳腺癌的疗效及其与uPA、PAI-1组织表达的相关性分析

全文: PDF(1925 KB)
输出: BibTeX | EndNote (RIS)

摘要目的分析新辅助化疗治疗乳腺癌的疗效及其与uPA、PAI-1组织表达的相关性。方法搜集2012年3月至2014年5月来我院就诊的乳腺癌患者82例,均给以新辅助化疗,采用免疫组织化学法检测化疗后所有乳腺癌组织中uPA及PAI-1的表达情况,探讨新辅助化疗的疗效及与uPA、PAI-1表达的相关性。结果 uPA和PAI-1组织表达与治疗效果均呈负相关(-1≤r＜0),相关系数的检验具有统计学意义(P＜0.05)。结论 uPA和PAI-1组织表达与治疗效果存在相关性,表现为uPA及PAI-1表达水平呈阴性,患者治疗效果好。

	服务

	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ： uPA, PAI-1, 新辅助化疗, 乳腺癌

Abstract：Objective To investigate the correlations between uPA, PAI-1 expression and neoadjuvant chemotherapy in the treatment of breast cancer.Methods We collected 82 cases of breast cancer patients who received treatment in our hospital from May 2014 to March 2012. All the patients were treated with breast cancer resection and neoadjuvant chemotherapy after surgery. Levels of UPA and PAI-1 expression in breast carcinoma tissue were detected by immunohistochemistry examination. The correlations between uPA, PAI-1 expression and the effect of neoadjuvant chemotherapy on breast cancer were analyzed.Results The expression of uPA and PAI-1 was negatively correlated with the effect of neoadjuvant chemotherapy on breast cancer(-1≤r＜0,P＜0.05).Conclusion The positive expression of uPA and PAI-1 is correlated with the effect of neoadjuvant chemotherapy on breast cancer, suggesting that uPA and PAI-1 could be used as negative biomarkers of therapeutic effect.

Key words： uPA PAI-1 neoadjuvant chemotherapy breast cancer

收稿日期: 2016-01-27 出版日期: 2017-01-05

基金资助:河北省科技计划项目(No.152777107D)

引用本文:

杨帆, 王丽, 刘运江, 孔祥顺,刘登湘. 新辅助化疗治疗乳腺癌的疗效及其与uPA、PAI-1组织表达的相关性分析[J]. 解放军预防医学杂志, 2016, 34(6): 894-895.
YANG Fan, WANG Li, LIU Yunjiang, KONG Xiangshun, LIU Dengxiang. Effect of Neoadjuvant Chemotherapy on Breast Cancer and Correlation with Expression of uPA and PAI-1. Journal of Preventive Medicine of Chinese People's Liberation Army, 2016, 34(6): 894-895.

链接本文:

http://manu37.magtech.com.cn/Jwk_jsyxkx/jfj/CN/ 或 http://manu37.magtech.com.cn/Jwk_jsyxkx/jfj/CN/Y2016/V34/I6/894

[1]	陈旭伟,孙伟,崔世义.uPA、PAI-1 的表达和MVD 计数与浸润性乳腺癌侵袭性的关系[J].现代生物医学进展,2011,11(12):2307.
[2]	董欢,林燕苹,应学翔,等.uPA/ PAI-1在乳腺癌中的表达及其临床意义的研究进展[J].复旦学报(医学版),2012,39(6):671.
[3]	吴家豪,何劲松,倪勇,等.乳腺癌新辅助化疗疗效评价方法进展[J].癌症,2010,29(2):240.
[4]	王丽,宋兰英,刘运江.乳腺癌组织uPA 和PAI-1表达与临床病理因素相关性的探讨[J].中华肿瘤防治杂志,2009,16(22):1765.
[5]	牟鹏,厉红元.乳腺癌新辅助化疗的研究进展[J].中国普外基础与临床杂志,2011,18(9):1011.
[6]	BUTA M,DODI R,URI I,et al.Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression,during an early follow-up[J].Tumour Biol,2015,36(10):8193.
[7]	范建,杨华英,孙冬霞,等.uPA和FAK在肝癌组织中的表达及相关性研究[J].现代中西医结合杂志,2013,22(6):589.
[8]	HARMS W,MALTER W,KRMER S,et al.Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer[J].Anticancer Res,2014,34(8):4457.
[9]	张淑群,魏媛媛,马一楠,等.uPA在三阴性乳腺癌组织中的表达及临床意义[J].现代肿瘤医学,2014(7):1567.
[10]	JANICKC F,PRCCHTL A,THOMSSEN C.Randomized adjuvant chemotherapy trial in high risk, lymph node negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1[J].J Natl Cancer Inst,2011,93(12):913.